Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Liu, Yanchun ^a   Yang, Hui ^b   Chen, Tianxing ^b   Luo, Yongbin ^a   Xu, Zheyuan ^b   Li, Ying ^b   Yang, Jiahui ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b First People s Hospital of Yunnan Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADENOCARCINOMA CELL LINE; APOPTOSIS; ARTICLE; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84929325553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127092     Document Type: Article

References (51)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England journal of medicine. 2008; 359 (13):1367-80. doi: 10.1056/NEJMra0802714 PMID: 18815398.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90. doi: 10.3322/caac.20107 PMID: 21296855.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64 (1):9-29. doi: 10.3322/caac.21208 PMID: 24399786.
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. The New England journal of medicine. 2004; 350(4):379-92. doi: 10.1056/NEJMra035536 PMID: 14736930.
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19 (56):6550-65. doi: 10.1038/sj.onc.1204082 PMID: 11426640.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004; 350(21):2129-39. doi: 10.1056/ NEJMoa040938 PMID: 15118073.
7. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metellus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014; 25(1):126-31. doi: 10.1093/annonc/mdt418 PMID: 24285021; PubMed Central PMCID: PMC3868323.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. doi: 10.1126/ science.1099314 PMID: 15118125.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010; 362 (25):2380-8. doi: 10.1056/NEJMoa0909530 PMID: 20573926.
10. Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. The Journal of pharmacology and experimental therapeutics. 2014; 351(1):67-76. doi: 10. 1124/jpet.114.217141 PMID: 25073473.
11. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer cell. 2010; 17(1):77-88. doi: 10.1016/j.ccr.2009.11.022 PMID: 20129249; PubMed Central PMCID: PMC2980857.
12. Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, et al. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncology reports. 2013; 30 (2):623-36. doi: 10.3892/or.2013.2512 PMID: 23728071.
13. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The lancet oncology. 2011; 12 (2):175-80. doi: 10.1016/S1470-2045(10)70087-5 PMID: 21277552.
14. Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Current opinion in pharmacology. 2013; 13(3):394-401. doi: 10.1016/j.coph.2013.03.010 PMID: 23608109.
15. Cadranel J, Ruppert AM, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical reviews in oncology/hematology. 2013; 88(3):477-93. doi: 10. 1016/j.critrevonc.2013.06.009 PMID: 23911281.
16. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. The Journal of biological chemistry. 1992; 267(36):26181-90. PMID: 1334494.
17. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Molecular and cellular biology. 2001; 21(24):8329-35. doi: 10.1128/ MCB.21.24.8329-8335.2001 PMID: 11713269; PubMed Central PMCID: PMC99997.
18. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (nonneoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leukemia research. 2011; 35(10):1390-4. doi: 10.1016/j.leukres.2011.06.021 PMID: 21813176; PubMed Central PMCID: PMC3163753.
19. Minami Y, Oishi I, Endo M, Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Developmental dynamics: an official publication of the American Association of Anatomists. 2010; 239(1):1-15. doi: 10.1002/ dvdy.21991 PMID: 19530173.
20. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(2):396-404. doi: 10. 1158/1078-0432.CCR-07-1823 PMID: 18223214.
21. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PloS one. 2011; 6(6):e21018. doi: 10.1371/journal.pone.0021018 PMID: 21698301; PubMed Central PMCID: PMC3115963.
22. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. The American journal of pathology. 2012; 181 (6):1903-10. doi: 10.1016/j.ajpath.2012.08.024 PMID: 23041612; PubMed Central PMCID: PMC3509760.
23. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PloS one. 2012; 7(3):e31127. doi: 10. 1371/journal.pone.0031127 PMID: 22403610; PubMed Central PMCID: PMC3293865.
24. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Scientific reports. 2014; 4:5811. doi: 10.1038/srep05811 PMID: 25056203; PubMed Central PMCID: PMC4108928.
25. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PloS one. 2013; 8(4):e61167. doi: 10.1371/journal.pone. 0061167 PMID: 23593420; PubMed Central PMCID: PMC3620154.
26. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF- 1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer cell. 2012; 21(3):348-61. doi: 10.1016/j.ccr.2012.02.008 PMID: 22439932.
27. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, et al. The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy. Seminars in cancer biology. 2014; 29:21-31. doi: 10.1016/j.semcancer.2014.07.005 PMID: 25068995.
28. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. International journal of cancer Journal international du cancer. 2008; 123(5):1190-5. doi: 10.1002/ijc.23587 PMID: 18546292.
29. Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grander D, et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leukemia & lymphoma. 2013; 54(4):843-50. doi: 10.3109/10428194.2012.731599 PMID: 22988987.
30. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leukemia & lymphoma. 2008; 49(7):1360-7. doi: 10.1080/ 10428190802124000 PMID: 18604725.
31. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2007; 28(6):318-26. doi: 10.1159/000121405 PMID: 18354269.
32. Xu J, Zeng GZ, Chen KL, Liu YM, Sun ZH, Tan NH, et al. A new lignan glycoside from Chamaecyparis obtusa var. breviramea f. crippsii. Natural product communications. 2014; 9(2):215-6. PMID: 24689293.
33. Ma LJ, Wang HZ, Bian L, Shao WP, Tang RZ, Wang QQ, et al. [Establishment and characterization of lung adenocarcinoma cell line XLA-07]. Zhonghua bing li xue za zhi Chinese journal of pathology. 2012; 41(5):335-9. doi: 10.3760/cma.j.issn.0529-5807.2012.05.011 PMID: 22883674.
34. Zhao YM, Su B, Yang XJ, Shi JY, Tang L, Zhang J, et al. [Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2013; 35(2):103-8. doi: 10.3760/cma.j.issn.0253-3766.2013.02.006 PMID: 23714663.
35. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002; 297 (5578):63-4. doi: 10.1126/science.1073096 PMID: 12098689.
36. Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Science signaling. 2013; 6(294):re6. doi: 10.1126/scisignal.2004652 PMID: 24065147; PubMed Central PMCID: PMC3876281.
37. Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer biology & therapy. 2013; 14(4):304-14. doi: 10.4161/cbt.23627 PMID: 23358468; PubMed Central PMCID: PMC3667869.
38. Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L, et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PloS one. 2013; 8(10):e78339. doi: 10.1371/journal.pone.0078339 PMID: 24205204; PubMed Central PMCID: PMC3813472.
39. Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(2):793-8. doi: 10.1073/pnas.1308374111 PMID: 24379361; PubMed Central PMCID: PMC3896194.
40. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei P, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. British journal of haematology. 2010; 151(4):327-35. doi: 10.1111/j.1365-2141.2010.08362.x PMID: 20813009.
41. Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. 2012; 26(6):1348-55. doi: 10.1038/leu.2011.362 PMID: 22289919.
42. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. doi: 10.1182/blood-2010-05-283309 PMID: 20702778; PubMed Central PMCID: PMC2996114.
43. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330 PMID: 23620405; PubMed Central PMCID: PMC3804130.
44. Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Translational lung cancer research. 2014; 3(3):122-30. doi: 10.3978/j.issn.2218-6751.2014. 03.02 PMID: 25806291; PubMed Central PMCID: PMC4367691.
45. Bichev SN, Marinova DM, Slavova YG, Savov AS. Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients. Cellular oncology. 2014. doi: 10.1007/s13402-014-0211- 7 PMID: 25534657.
46. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature reviews Cancer. 2007; 7(10):778-90. doi: 10.1038/nrc2190 PMID: 17882278.
47. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers-a review. European journal of cancer. 2012; 48(9):1299-311. doi: 10.1016/j.ejca.2012.03.007 PMID: 22464348.
48. Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A, Khan AS, Mikaelsson E, Osterborg A, et al. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. British journal of haematology. 2015; 169(3):455-8. doi: 10.1111/bjh.13228 PMID: 25407287.
49. Bainbridge TW, DeAlmeida VI, Izrael-Tomasevic A, Chalouni C, Pan B, Goldsmith J, et al. Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains. PloS one. 2014; 9 (7):e102695. doi: 10.1371/journal.pone.0102695 PMID: 25029443; PubMed Central PMCID: PMC4100928.
50. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer research. 2011; 71(8):3132-41. doi: 10.1158/0008-5472.CAN-10- 2662 PMID: 21487037.
51. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. International journal of cancer Journal international du cancer. 2014; 135(10):2305-16. doi: 10.1002/ijc.28879 PMID: 24706440.